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Background: In 2002, the World Health Organization recommended that artemisinin-based combination therapy (ACT)
be used to treat uncomplicated malaria. Dihydroartemisinin-piperaquine and artesunate-pyronaridine are two of these
new combinations. The aim of the present work was to assess the distribution of the in vitro values of pyronaridine (PND)
and piperaquine (PPQ) and to define a cut-off for reduced susceptibility for the two anti-malarial drugs.
Methods: The distribution and range of the 50% inhibitory concentration values (IC50) of PND and PPQ were determined
for 313 isolates obtained between 2008 and 2012 from patients hospitalized in France for imported malaria. The statistical
Bayesian analysis was designed to answer the specific question of whether Plasmodium falciparum has different
phenotypes of susceptibility to PND and PPQ.
Results: The PND IC50 values ranged from 0.6 to 84.6 nM, with a geometric mean of 21.1 ± 16.0 nM (standard deviation).
These values were classified into three components. The PPQ IC50 values ranged from 9.8 to 217.3 nM, and the geometric
mean was 58.0 ± 34.5 nM. All 313 PPQ values were classified into four components. Isolates with IC50 values greater than
60 nM or four-fold greater than 3D7 IC50 are considered isolates that have reduced susceptibility to PND and those with
IC50 values greater than 135 nM or 2.3-fold greater than 3D7 IC50 are considered isolates that have reduced susceptibility
to PPQ.
Conclusion: The existence of at least three phenotypes for PND and four phenotypes for PPQ was demonstrated.
Based on the cut-off values, 18 isolates (5.8%) and 13 isolates (4.2%) demonstrated reduced susceptibility to PND
and PPQ, respectively.
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Over the past 20 years, many strains of Plasmodium falcip-
arum have become resistant to chloroquine and other anti-
malarial drugs. In 2002, the World Health Organization
(WHO) recommended that artemisinin-based combination
therapy (ACT) be used to treat all cases of uncomplicated
malaria. The following combinations have been evaluated:* Correspondence: bruno.pradines@free.fr
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unless otherwise stated.artesunate-sulphadoxine-pyrimethamine, artesunate-amo-
diaquine, artemether-lumefantrine, artesunate-mefloquine,
artesunate-chlorproguanil-dapsone and, more recently,
artesunate-pyronaridine and dihydroartemisinin-pipera-
quine. Most of these combinations are available as
fixed-dose co-formulations that are convenient, facili-
tate improved adherence and help prevent misuse.
Dihydroartemisinin-piperaquine (DP) (Artekin®, Duo-
Cotecxin®, Eurartesim®) is a new ACT that is administered
as single daily dose for three days. It has been demon-
strated to be well tolerated and highly effective for the
treatment of uncomplicated malaria in Asia [1,2] and for
the treatment of uncomplicated P. falciparum malaria in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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prophylactic effect than does artemether-lumefantrine
[7-9] and artesunate-amodiaquine [10]. Since 2012, DP
has been available for the treatment of uncomplicated fal-
ciparum malaria in France. DP has also been demon-
strated to be effective for the treatment of Plasmodium
vivax malaria [11]. However, the emergence of P. falcip-
arum resistance to DP, manifested as delayed parasite
clearance following the treatment, has developed in
Cambodia and Vietnam [12-14].
The piperaquine (PPQ) susceptibility of P. falciparum iso-
lates has been assessed in studies with isolates from Africa
(geometric mean IC50 = 81.3 nM and 66.8 nM) [15,16],
Cameroon (39 nM) [17], Kenya (from 41.9 to 50 nM)
[18-20], Niger (24.2 nM) [21], Ghana (28.3 nM) [22],
Uganda (6.1 nM) [23], the China-Myanmar border (28.4
nM) [24], the Thai-Burmese border (49 nM) [25], Cambodia
(22 nM) [26], Indonesia (21.8 nM) [27], and Papua New
Guinea [28].
The pyronaridine-artesunate combination (Pyramax®) is
one of the latest artemisinin-based combinations and is cur-
rently under development by the not-for-profit organization
Medicines for Malaria Venture (Geneva, Switzerland) and
the pharmaceutical company Shin Poong Pharmaceuticals
(Seoul, Republic of Korea) for the treatment of uncompli-
cated P. falciparum malaria and for the blood stages of P.
vivax malaria. Pyramax® has recently completed phase III
trials in humans. A five-day regimen of pyronaridine (PND)
alone (total dose = 1,800 mg) produced a better cure rate
than did artesunate, artemether or mefloquine used alone
in the same conditions in Thailand [29]. The efficacy of
PND-artesunate was not inferior to that of artemether-
lumefantrine in the treatment of uncomplicated falciparum
malaria in Africa and Southeast Asia [30,31]. PND-
artesunate had a better efficacy than did mefloquine-
artesunate in Cambodia [32].
The PND in vitro susceptibility was previously assessed
in P. falciparum strains (1.9 to 47.8 nM and 15 to 49 nM,
respectively) [33,34] and in isolates from Africa (geometric
mean = 19.9 nM) [16], Cameroon (3.58 nM) [35], Gabon
(3.0 nM and 1.87 nM) [36,37], Kenya (13.5 nM) [19],
Niger (9.8 nM) [21], Senegal (3.8 nM and 4.52 nM)
[38,39], Indonesia (1.92 nM) [40], and in isolates from pa-
tients in Thailand that were cured with PND (15.7 nM) or
that recrudesced after PND treatment (23.0 nM) [29]. In
addition, PND is effective in vitro against P. vivax isolates
(2.58 nM) [40].
The early detection of resistance to PPQ and PND
requires the establishment of the baseline parasite che-
mosusceptibility of current isolates from regions of en-
demicity. The aim of the present work was to determine
the distribution and range of the 50% inhibitory concen-
trations (IC50) of PPQ and PND for 313 imported mal-
aria isolates from Africa and to determine the cut-offvalues for in vitro reduced susceptibility to these two
drugs.
Methods
Patients and sample collection
In total, 313 P. falciparum isolates were collected between
April 2008 and August 2012 from patients hospitalized in
France with imported malaria from a malaria-endemic
country (Angola, Benin, Burkina Faso, Cameroon, Cen-
tral African Republic, Chad, Comoros, Congo, Ivory
Coast, Gabon, Gambia, Ghana, Guinea, Madagascar,
Mali, Mauritania, Mozambique, Niger, Senegal, Togo,
Zambia). Informed consent was not required for this
study because the sampling procedures and testing are
part of the French national recommendations for the
care and surveillance of malaria. Venous blood samples
were collected in Vacutainer® ACD tubes (Becton Dickinson,
Rutherford, NJ, USA) before treatment and were trans-
ported at 4°C from French hospitals located in Aix en
Provence, Bordeaux, Chambery, Frejus, Grenoble, Lyon,
Marseille, Metz, Montpellier, Nice, Nimes, Pau, Toulon,
Toulouse, and Valence to the Institute of Biomedical Re-
search of the French Army (IRBA) in Marseille within
72 hours of collection. A Case Report Form was provided at
the same time, either as a paper copy or electronically.
Thin blood smears were stained using a RAL® kit (Réac-
tifs RAL, Paris, France) and were examined to determine
the P. falciparum density and confirm mono-infection. Par-
asitized erythrocytes were washed three times with RPMI
1640 medium (Invitrogen, Paisley, UK), buffered with
25 mM HEPES and 25 mM NaHCO3. If the parasitaemia
exceeded 0.5%, the infected erythrocytes were diluted to
0.5% with uninfected erythrocytes (human blood type A+)
and re-suspended in RPMI 1640 medium supplemented
with 10% human serum (Abcys S.A. Paris, France) for a
final haematocrit of 1.5%. The susceptibility of the 313 iso-
lates was assessed without culture adaptation.
Drugs
PPQ and PND were obtained from Shin Poong Pharm
Co. (Seoul, Korea). PPQ was first dissolved in methanol
and then diluted in water to obtain final concentrations
ranging from 0.8 to 1,000 nM. PND was dissolved and
diluted in water to obtain concentrations ranging from
0.15 to 100 nM.
Batches of plates were tested and validated using the
chloroquine-susceptible strain 3D7 (isolated in West
Africa; obtained from MR4, VA, USA) in three to six in-
dependent experiments using the conditions described
below. The two strains were synchronized twice with
sorbitol before use [41], and clonality was verified every
15 days through PCR genotyping of the polymorphic
genetic markers msp1 and msp2 and microsatellite loci
[42,43]; additionally, clonality was verified each year by
Figure 1 Piperaquine and pyronaridine median 50% inhibitory
concentrations (IC50 values in nM) of 313 Plasmodium falciparum
isolates.
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malarial Resistance Network (WWARN).
Ex vivo assay
For ex vivo isotopic microtests, 200 μl/well of the suspen-
sion of parasitized red blood cells (final parasitaemia,
0.5%; final haematocrit, 1.5%) were distributed in 96-well
plates pre-dosed with anti-malarial drugs. Parasite growth
was assessed by adding 1 μCi of tritiated hypoxanthine
with a specific activity of 14.1 Ci/mmol (Perkin-Elmer,
Courtaboeuf, France) to each well at time zero. The plates
were then incubated for 42 hours in controlled atmos-
pheric conditions that consisted of 10% O2, 5% CO2 and
85% N2 at 37°C with a humidity of 95%. Immediately after
incubation, the plates were frozen and then thawed to lyse
the erythrocytes. The contents of each well were collected
on standard filter microplates (Unifilter GF/B; Perkin-
Elmer) and washed using a cell harvester (Filter-Mate Cell
Harvester; Perkin-Elmer). The filter microplates were
dried, and 25 μl of scintillation cocktail (Microscint O;
Perkin-Elmer) was placed in each well. Radioactivity incor-
porated in nucleotides by the parasites was measured with
a scintillation counter (Top Count; Perkin-Elmer).
The drug concentration able to inhibit 50% of the para-
site growth (IC50) was assessed by the drug concentration
corresponding to 50% of the incorporation of tritiated
hypoxanthine by the parasite in the drug-free control
wells. The IC50 value was determined using a non-linear
regression analysis of log-based dose-response curves
(Riasmart, Packard, Meriden, USA).
Statistical analysis
The statistical analysis was designed to answer the specific
question of whether P. falciparum has different PPQ and
PND susceptibility phenotypes. A heterogeneous popula-
tion of IC50 values was observed; therefore, the data were
assumed to represent a univariate Gaussian mixture with
k components. Each observation was assumed to originate
from one of the k components, and the label of the group
from which each observation arose was unknown. The un-
knowns of the model were the number of components,
the means, variances and weights of the different compo-
nents, and the vector of allocations of the observations.
The analysis was performed in two steps. First, reversible
jump Monte Carlo Markov Chains (RJMCMC) [44]
samplers were used to choose a suitable number of com-
ponents k, and the present algorithm followed the recom-
mendations of Cappé et al. [45]. After a relevant number
of components was chosen, standard Gibbs samplers were
run to obtain estimates of the model parameters and to
classify the observations [46]. Because of the ‘label-switch-
ing’ problem that is due to the symmetry in the likelihood
of the model parameters, the mixture components should
be labelled before making an inference regarding theparameters [47]. The classical ordering constraint, which
was biologically relevant here, was used. The algorithms
were run for 100,000 burn-in iterations and 20,000 post-
burn-in iterations. These numbers were assumed to be
sufficient to obtain reliable results. Moreover, each algo-
rithm was run three times to verify that the results ob-
tained in two different runs were similar and that there
was no convergence problem [44].
Results
The PND IC50 values ranged from 0.6 to 84.6 nM
(Figure 1). The geometric mean was 21.1 ± 16.0 nM
(standard deviation). The average parameter estimates
for the IC50 values by year are given in Table 1. There
was no significant difference in the PND responses be-
tween the five years (p = 0.9416, Kruskal-Wallis rank
sum test). In addition, there was no significant difference
in the responses to PND against the strain 3D7, which
was used as a control for the plate batches (p = 0.8904).
The triple normal distribution model for PND is rep-
resented in Figure 2. The parameter estimates for the
three-component mixture model, including the number
of isolates in each normal distribution, the mean of the
IC50 values and the standard deviation (SD) for each dis-
tribution, are summarized in Table 2.
The cut-off value for in vitro reduced susceptibility to
PND was estimated using the arithmetic mean plus two
SDs of the IC50s of the 309 isolates and was set at 57.7
nM. Isolates with an IC50 greater than 60 nM were con-
sidered to display reduced susceptibility to PND in vitro.
Eighteen isolates (5.8%) displayed reduced susceptibility
to PND in vitro.
The PPQ IC50 values ranged from 9.8 to 217.3 nM
(Figure 1). The geometric mean was 58.0 ± 34.5 nM
(standard deviation). The average parameter estimates
for the IC50 values by year are given in Table 3. There
was a significant difference in the PPQ responses
Table 2 Parameter estimates for the three-component
mixture model for the pyronaridine (PND) distribution of
the 309 Plasmodium falciparum isolates
Component Isolates
number




A 182 58.9 15.1 5.6
B 96 31.1 33.9 5.3
C 31 10.0 59.7 12.2
Table 1 Statistical analysis of the 309 pyronaridine (PND)
IC50 values by year
Year IC50 number Mean (nM) SD IC50 min IC50 max
2008 60 21.4 14.5 3.8 67.4
2009 92 21.9 15.2 3.2 76.1
2010 88 19.4 15.7 0.6 80.0
2011 47 23.0 18.3 6.2 75.3
2012 22 21.1 19.3 9.1 84.6
Total 309 21.1 16.0 0.6 84.6
SD: standard deviation.
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sum test). However, there was no significant difference
in the responses to PPQ against the strain 3D7, which
was used as a control for the plate batches (p = 0.6909).
The quadruple normal distribution model for PPQ is
presented in Figure 3. The parameter estimates for the
quadruple-component mixture model, including the num-
ber of isolates in each normal distribution, the mean of
the IC50 values and the standard deviation for each distri-
bution, are summarized in Table 4.
The cut-off for in vitro reduced susceptibility to PPQ
was estimated using the arithmetic mean plus 2 SDs of the
IC50s of the 313 isolates and was found to be 135.4 nM.
Isolates with an IC50 greater than 135 nM were considered
to be isolates with reduced susceptibility to PPQ in vitro.
Thirteen isolates (4.2%) displayed reduced susceptibility to
PPQ in vitro.
Discussion
The early detection of resistance to PPQ and PND re-
quires that the baseline parasite chemosusceptibility of
current isolates from regions of endemicity be established.Figure 2 Distribution of the pyronaridine IC50 values of the 309
Plasmodium falciparum isolates in the three-component mixture
model (Bayesian mixture modelling approach). The dotted lines
represent the three fitted mixtures.Maximizing the efficacy and longevity of drugs as a tool to
control malaria will critically depend on pursuing inten-
sive research into identifying in vitro markers and imple-
menting in vitro and in vivo surveillance programmes,
such as those championed by WWARN [48,49]. In this
context, there is a need to identify in vitro and molecular
markers that predict PPQ and PND resistance and can
provide an active surveillance method to monitor tem-
poral trends in parasite susceptibility [50,51].
A Bayesian mixture modeling approach was choose. A
Bayesian approach has already been proposed for anti-
malarial in vitro susceptibilities; it has been used to evaluate
the distribution and the cut-off for reduced susceptibility to
doxycycline [52,53]. All 309 PND values were classified into
three components: component A (IC50 mean 15.1 nM),
component B (IC50 mean 33.9 nM) and component C
(IC50 mean 59.7 nM). The proportion of isolates in each
group was 58.9% for component A, 31.1% for component B
and 10.0% for component C. In the previous study on
doxycycline, the distribution of the doxycycline IC50 in a
triple normal distribution was independent of the African
origin of the isolates (imported isolates from Africa or field
isolates from Senegal, Gabon or Congo) [52]. Only the pro-
portion of isolates predicted to belong to each component
was dependent on the origin of the isolates.
In the present study, the cut-off for in vitro reduced
susceptibility to PND was estimated as the geometric
mean plus 2 SDs of the IC50s of the 309 isolates (57.7
nM). Isolates with an IC50 greater than 60 nM were con-
sidered to be isolates with reduced in vitro susceptibility
to PND. Eighteen isolates (5.8%) demonstrated reduced
susceptibility to PND in vitro. These data are consistentTable 3 Statistical analysis of the 313 piperaquine (PPQ)
IC50 values by year
Year IC50 number Mean (nM) SD IC50 min IC50 max
2008 60 77.8 40.5 20.6 217.3
2009 95 70.6 30.6 14.0 189.0
2010 89 44.0 23.4 11.8 92.3
2011 47 44.6 20.9 11.8 123.0
2012 22 59.7 46.2 9.8 196.0
Total 313 58.0 34.5 9.8 217.3
SD: standard deviation.
Figure 3 Distribution of the piperaquine IC50 values of the 313
Plasmodium falciparum isolates in the four-component mixture
model (Bayesian mixture modelling approach). The dotted lines
represent the three fitted mixtures.
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One study of isolates in Niger reported that 3% of the
isolates displayed in vitro resistance to PND, with an es-
timated cut-off of 20 nM [21].
A cut-off for in vitro resistance is defined for a specific
methodology. For example, the in vitro effects and the
IC50 values for doxycycline are dependent on the time in-
cubation conditions [14-16], on gas conditions, i.e., O2
and CO2 [54,55] and on methodology, i.e., isotopic test
versus immuno-enzymatic or SYBR green test [56,57]. The
incubation time is the condition that interferes signifi-
cantly with the IC50 values for doxycycline or other antibi-
otics [58,59]. The IC50 values decrease by a factor between
10 to 100 in prolonged exposure to antibiotics. The gas
conditions interfere with the IC50 values for quinolines,
such as chloroquine, monodesethyaodiaquine, quinine,
mefloquine, or lumefantrine [55,60]. The IC50 values for
quinoline drugs are significantly lower at O2 > 15% than
those at 10% O2. Dissolution methods to prepare the stock
solutions of anti-malarial drugs can also interfere with
IC50 values. In the present study, the dissolution of PND
in water was the same condition as this used in previous
work [16,36,37,61]. Using an arbitrarily fixed threshold of
resistance could lead to wrong decision making at theTable 4 Parameter estimates for the four-component
mixture model for the piperaquine PPQ) distribution
of the 313 Plasmodium falciparum isolates
Component Isolates
number




A 136 43.5 35.4 11.4
B 146 46.6 76.7 12.6
C 22 7.0 103.5 20.4
D 9 2.9 175.0 26.2country level. To reduce the effects of the conditions of
the methodology of the in vitro test, an IC50 ratio (IC50 of
clinical isolate/mean IC50 of 3D7 on the same batch of
plates) can be evaluated for each isolate [56]. Another
mean is to use a cut-off ratio (resistance cut-off defined
for a specific methodology/mean IC50 of 3D7 tested by the
same methodology). Isolates with cut-off ratio greater than
four (60/16.7), i.e., isolates with IC50 four-fold greater than
3D7 IC50, are considered to be isolates with reduced
in vitro susceptibility to PND. Compared to 3D7 IC50
values, the data obtained with different methodologies can
be compared.
All 313 PPQ values were classified into four compo-
nents: component A (IC50 mean 35.4 nM), component B
(IC50 mean 76.7 nM), component C (IC50 mean 103.5
nM), and component D (IC50 mean 175.0 nM). The pro-
portion of isolates in each group was 43.5% for compo-
nent A, 46.6% for component B, 7.0% for component C,
and 2.9% for component D.
In the present study, PPQ was dissolved in methanol and
then diluted in water. In previous works, PPQ was dis-
solved in methanol and then diluted in water [13,14,24,25],
in methanol and hydrochloric acid and then diluted in
water [20,62], in dimethyl sulphoxide (DMSO) [27,63] or in
0.5% acid lactic in water [15,28,63-65]. These several dissol-
ution methods to prepare the PPQ stock solutions can
interfere with IC50 values. The cut-off for in vitro reduced
susceptibility to PPQ was estimated to be the geometric
mean plus 2 SDs of the IC50s of the 313 isolates (135.4
nM). Isolates with an IC50 greater than 135 nM or 2.3-fold
greater than PPQ IC50 for 3D7 were considered to be iso-
lates with reduced in vitro susceptibility to PPQ. Thirteen
isolates (4.2%) met the criteria for reduced susceptibility to
PPQ in vitro. These data are consistent with previous data
from Niger but not from the China-Myanmar border. In
Niger, 6% of the isolates were found to be resistant to PPQ
in vitro, with an estimated cut-off of 150 nM [21]. However,
83% of the isolates from the China-Myanmar border were
resistant to PPQ in vitro (the cut-off of approximately 15
nM was estimated by a three-fold decrease in susceptibility
to PPQ in comparison to the strain 3D7) [24].
There was a significant difference in the PPQ responses
among the five years of the study (p <0.0001, Kruskal-Wallis
rank sum test). However, there was no significant difference
in the responses to PPQ against 3D7 (geometric mean each
year from 2008 to 2012: 56.7 nM, 58.4 nM, 61.0, 57.2 nM,
and 62.5 nM; p = 0.6909). This absence of significant differ-
ence in the responses of the control strains makes bias due
to the methodology unlikely.
The existence of at least three phenotypes for PND
and four phenotypes for PPQ was demonstrated. These
phenotypes may be associated with different genotypes.
Genotyping analysis would be necessary to identify the
molecular basis of the susceptibility differences and to
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vious work demonstrated that the doxycycline pheno-
types predicted by the Bayesian method were associated
with specific genotypes [53,63]. The priority now is to
investigate polymorphisms both in the genes that are
known to be involved in anti-malarial drug resistance
and in new genes for each phenotype.
Conclusion
The PND and PPQ in vitro susceptibility values ranged into
three and four components, respectively. Eighteen isolates
(5.8%) and 13 isolates (4.2%) demonstrated reduced in vitro
susceptibility to PND and PPQ, respectively. DP is associ-
ated with a longer prophylactic time after treatment com-
pared to the time after artemether-lumefantrine treatment
[5,6,64]. However, the gametocyte carriage and malaria
transmission to mosquitoes was lower after artemether-
lumefantrine treatment [66]. Despite the recent report of
frequent DP failures in Cambodia and Vietnam [12-14], DP
remains an effective treatment for falciparum malaria in
Africa and for P. vivax [67-69]. PND-artesunate is effective
for the treatment of uncomplicated falciparum malaria in
Africa and Southeast Asia [30,31]. PND-artesunate suc-
cessfully treats artemisinin-resistant Plasmodium berghei
parasites, while artemether-lumefantrine, artesunate-amo-
diaquine, artesunate-mefloquine and dihydroartemisinin-
piperaquine are not effective [70]. Although extended
parasite clearance times were indicative of artemisinin re-
sistance, ACT remains important for the treatment of
malaria.
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